Publications

Publications

ARTICLE

Inhibitors of dihydroorotate dehydrogenase cooperate with molnupiravir and N4-hydroxycytidine to suppress SARS-CoV-2 replication

Kim M. Stegmann et al.
iScience
Published: May 20, 2022
https://doi.org/10.1016/j.isci.2022.104293

 

ARTICLE

A Pilot Study of Vidofludimus Calcium for Treatment of Primary Sclerosing Cholangitis

Elizabeth J. Carey, John Eaton, Mitchell Clayton, Andrea Gossard, Sara Iqbal, Hamid Ullah, Nan Zhang, Richard Butterfield, Keith D. Lindor
Hepatology Communications
Published: March 3, 2022
https://doi.org/10.1002/hep4.1926

POSTER PRESENTATION

17th Congress of ECCO (European Crohn’s and Colitis Organization)

Wednesday, February 16, 2022 – Saturday, February 19, 2022

PRESENTATION

IMU-935: Phase 1 SAD/MAD Data in Healthy Human Subjects and Preclinical Update

Tuesday, December 14, 2021

Play Audio Recording

PRESENTATION

B&T Cell-Mediated Autoimmune Disease Drug Development Summit

Wednesday, October 6, 2021

POSTER PRESENTATION

50th Annual European Society for Dermatological Research (ESDR) Meeting

Wednesday, September 22, 2021 – Saturday, September 25, 2021

PRESENTATION

Virtual R&D Day: Update on the Preclinical and Clinical Development of IMU-935

Monday, July 12, 2021

Play Audio Recording

POSTER PRESENTATION

The International Federation of Psoriasis Association’s 6th World Psoriasis & Psoriatic Arthritis Conference 2021

Wednesday, June 30, 2021 – Saturday, July 3, 2021

PRESENTATION

IMU-838 in Multiple Sclerosis: Phase 3 Program in RRMS & Phase 2 Trial in PMS

Thursday, July 1, 2021

Play Audio Recording

POSTER PRESENTATION

2021 Virtual AAN Annual Meeting

Saturday, April 17, 2021 – Thursday, April 22, 2021

Play Audio Recording

POSTER PRESENTATION

30th Annual Meeting of the Society for Virology

Wednesday, March 24, 2021 – Friday, March 26, 2021

PRESENTATION

Main Phase 2 Analysis IMU-838 in Moderate COVID-19 & Phase 2 Proof-of-Concept Study IMU-838 in PSC

February 18, 2021

Play Audio Recording

ARTICLE

Clinical Relevance of Intestinal Barrier Dysfunction in Common Gastrointestinal Diseases

Andreas Muehler, Jason R. Slizgi, Hella Kohlhof, Manfred Groeppel, Evelyn Peelen, Daniel Vitt
World Journal of Gastrointestinal Pathophysiology
Published: December 12, 2020
https://doi.org/10.4291/wjgp.v11.i6.114

ARTICLE

IMU-838, a Developmental DHODH Inhibitor in Phase II for Autoimmune Disease, Shows Anti-SARS-CoV-2 and Broad-Spectrum Antiviral Efficacy In Vitro

Friedrich Hahn, Christina Wangen, Sigrun Häge, Antonia Sophia Peter, Gerhard Dobler, Brett Hurst, Justin Julander, Jonas Fuchs, Zsolt Ruzsics, Klaus Überla, Hans-Martin Jäck, Roger Ptak, Andreas Muehler, Manfred Gröppel, Daniel Vitt, Evelyn Peelen, Hella Kohlhof, Manfred Marschall
Viruses
Published: December 5, 2020
https://doi.org/10.3390/v12121394

POSTER PRESENTATION

MSVirtual2020 / 8th Joint ACTRIMS-ECTRIMS Meeting

Friday, September 11, 2020 – Sunday, September 13, 2020

PRESENTATION

IMU-838 Phase 2 Data EMPhASIS Trial in RRMS

Friday, September 11, 2020

Play Audio Recording

ARTICLE

Novel Dihydroorotate Dehydrogenase Inhibitors with Potent Interferon-Independent Antiviral Activity Against Mammarenaviruses In Vitro

Yu-Jin Kim, Beatrice Cubitt, Yingyun Cai, Jens H. Kuhn, Daniel Vitt, Hella Kohlhof, Juan C. de la Torre
Viruses
Published: July 29, 2020
https://doi.org/10.3390/v12080821

ARTICLE

Vidofludimus Calcium, a Next Generation DHODH Inhibitor for the Treatment of Relapsing-Remitting Multiple Sclerosis

Andreas Muehler, Evelyn Peelen, Hella Kohlhof, Manfred Gröppel, Daniel Vitt
Multiple Sclerosis and Related Disorders
Published: May 6, 2020
https://doi.org/10.1016/j.msard.2020.102129

ARTICLE

Safety, Tolerability and Pharmacokinetics of Vidofludimus Calcium (IMU-838) After Single and Multiple Ascending Oral Doses in Healthy Male Subjects

Andreas Muehler, Hella Kohlhof, Manfred Groeppel, Daniel Vitt
European Journal of Drug Metabolism and Pharmacokinetics
Published: May 2, 2020
https://doi.org/10.1007/s13318-020-00623-7

ABSTRACT

Design, Rationale and Baseline Characteristics of the Randomized Double-blind Phase II Clinical Trial of Vidofludimus calcium (IMU-838) in Relapsing-Remitting Multiple Sclerosis (4558)

Robert Fox, Heinz Wiendl, Nicola De Stefano, Johann Sellner, Andreas Mühler
Neurology
Published: April 14, 2020

PRESENTATION

IBD Innovate Conference: Product Development for Crohn’s and Colitis

Wednesday, December 4, 2019
New York

ARTICLE

The Selective Oral Immunomodulator Vidofludimus in Patients with Active Rheumatoid Arthritis: Safety Results from the COMPONENT Study

Andreas Muehler, Hella Kohlhof, Manfred Groeppel, Daniel Vitt
Drugs in R&D
Published: October 16, 2019
https://doi.org/10.1007/s40268-019-00286-z

POSTER PRESENTATION

Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2019

Wednesday, September 11, 2019
Stockholm, Sweden

.